RSS
7 Dec 2019

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Author: admintech | Filed under: Press Release

NORTH CHICAGO, Ill., Dec. 7, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO®…

This entry was posted on Saturday, December 7th, 2019 at 8:20 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»